HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
QTTB
Q32 Bio Inc.
There isn't enough reported data to score QTTB yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
QTTB Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Strong |
QTTB's balance sheet is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
QTTB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 2.4x | $8.37 | -5.2% |
| Current | 2.6x | $8.82 | โ |
| Fair | 2.9x | $10.05 | +14% |
| Expensive | 4.8x | $16.68 | +89% |
Historical ranges are pointers, not guarantees.
QTTB's PE is 2.5x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
QTTB Forward outlook
There aren't enough analyst estimates for QTTB to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
QTTB has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus QTTB down 75%.
QTTB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$14.07 | +$26.61 |
| Q2 2024 | -$22.87 | +$18.17 |
| Q1 2024 | -$32.43 | +$6.81 |
| Q4 2023 | -$35.10 | -$33.48 |
| Q3 2023 | -$40.68 | -$38.16 |
| Q2 2023 | -$41.04 | -$39.42 |
| Q1 2023 | -$39.24 | -$37.08 |
| Q4 2022 | -$1.62 | +$29.52 |
QTTB has returned to profit: it earned $3.46 per share over the past year, after losing money the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was โ7.4% last quarter, down 9.4 points from the same quarter a year ago.
QTTB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $354K | -56% |
| Q1 2023 | $802K | 0% |
| Q4 2022 | $802K | 0% |
| Q3 2022 | $802K | -52% |
| Q2 2022 | $802K | -63% |
| Q1 2022 | $802K | -97% |
| Q4 2021 | $802K | -18% |
| Q3 2021 | $1.7M | +196% |
QTTB's revenue has slid since its 2021 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -8705% | -5176 points |
| Q1 2023 | -3430% | +1260 points |
| Q4 2022 | -4301% | -108 points |
| Q3 2022 | -4098% | -2269 points |
| Q2 2022 | -3530% | -2133 points |
| Q1 2022 | -4691% | -4687 points |
| Q4 2021 | -4193% | -1152 points |
| Q3 2021 | -1828% | +3158 points |
QTTB's operating margin was โ8705% last quarter, down 5176 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
QTTB has the stronger cash trend. Its trailing FCF is up 78% versus its history, compared with HIMS at down 84%.
QTTB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$6.3M | +$6.1M |
| Q4 2025 | -$6.2M | +$5.3M |
| Q3 2025 | -$4.2M | +$15.4M |
| Q1 2025 | -$12.5M | +$2.1M |
| Q4 2024 | -$11.4M | +$10.1M |
| Q3 2024 | -$19.6M | +$5.4M |
| Q2 2024 | -$22.2M | +$1.4M |
| Q1 2024 | -$14.6M | +$11.7M |
QTTB has burned cash in almost every quarter: โ$20M over the past year, against โ$66M the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
QTTB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -15.4x | Net Cash |
| Q2 2026 | -4.9x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.2x | Net Cash |
QTTB has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
QTTB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.1 | Neutral |
| Stochastic | 17.7 | Oversold |
QTTB's weekly RSI is 45 (neutral) and its Stochastic is 18 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | โ |
HIMS has no meaningful PE right now: it lost money over the past year.
QTTB PE vs Healthcare Sector
| Metric | QTTB | Sector median | Relative |
|---|---|---|---|
| PE | 2.6x | 26x | 90% below |
| PE % | 20 | 29 | 9 pts below |
QTTB is trading at 2.5x earnings, a 90% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
QTTB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.56 | 3% above |
| 20 week MA | $11.7 | 25% below |
| 50 week MA | $8.31 | 6.1% above |
| 100 week MA | $5.29 | 67% above |
| 200 week MA | $14.3 | 38% below |
QTTB has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to โ56% in 2021. It's down 42% so far in 2026.
QTTB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $388.6 | $227.7 | -41% |
| 2021 | $227.7 | $74.5 | -67% |
| 2022 | $74.5 | $21.4 | -71% |
| 2023 | $21.4 | $10.9 | -49% |
| 2024 | $10.9 | $3.36 | -69% |
| 2025 | $3.36 | $3.20 | -4.8% |
| 2026 YTD | $3.20 | $8.82 | +176% |
QTTB has the edge over HIMS on returns for 2026, with the stronger performance.